Fatty Acid Synthesis Pathway Genetic Variants and Clinical Outcome of Non-Small Cell Lung Cancer Patients after Surgery

被引:14
|
作者
Jin, Xin [1 ,2 ,3 ]
Zhang, Ke-Jin [5 ,6 ]
Guo, Xu [2 ,3 ]
Myers, Ronald [6 ]
Ye, Zhong [6 ]
Zhang, Zhi-Pei [4 ]
Li, Xiao-Fei [4 ]
Yang, Hu-Shan [6 ]
Xing, Jin-Liang [2 ,3 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp, Dept Pharm, Xian 710032, Peoples R China
[2] Fourth Mil Med Univ, Tangdu Hosp, Cell Engn Res Ctr, State Key Lab Canc Biol, Xian 710032, Peoples R China
[3] Fourth Mil Med Univ, Tangdu Hosp, Dept Cell Biol, Xian 710032, Peoples R China
[4] Fourth Mil Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian 710032, Peoples R China
[5] NW Univ Xian, Coll Life Sci, Xian 710069, Peoples R China
[6] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Med Oncol, Div Populat Sci, Philadelphia, PA 19107 USA
关键词
De novo lipogenesis; FASN; non-small cell lung cancer; prognosis; single nucleotide polymorphisms; ATP-CITRATE LYASE; THERAPEUTIC IMPLICATIONS; SYNTHASE EXPRESSION; PREDICTOR; SURVIVAL; SNPS; POLYMORPHISMS; INHIBITION; IMPACT; GROWTH;
D O I
10.7314/APJCP.2014.15.17.7097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Over-expression of de novo lipogenesis (DNL) genes is associated with the prognosis of various types of cancers. However, the effects of single nucleotide polymorphisms (SNPs) in these genes on recurrence and survival of non-small cell lung cancer (NSCLC) patients after surgery are still unknown. In this study, a total of 500 NSCLC patients who underwent surgery treatment were included. Eight SNPs in 3 genes (ACACA, FASN and ACLY) of the DNL pathway were examined using the Sequenom iPLEX genotyping system. Multivariate Cox proportional hazards regression and Kaplan-Meier curves were used to analyze the association of SNPs with patient survival and tumour recurrence. We found that two SNPs in the FASN gene were significantly associated with the recurrence of NSCLC. SNP rs4246444 had a significant association with lung cancer recurrence under additive model (hazard ratio [HR], 0.82; 95% confidence interval [95% CI], 0.67-1.00; p=0.05). Under the dominant model, rs4485435 exhibited a significant association with recurrence (HR, 0.75; 95% CI, 0.56-1.01; p=0.05). Additionally, SNP rs9912300 in ACLY gene was significantly associated with overall survival in lung cancer patients (HR, 1.41; 95% CI, 1.02-1.94, p=0.04) under the dominant model. Further cumulative effect analysis showed moderate dose-dependent effects of unfavorable SNPs on both survival and recurrence. Our data suggest that the SNPs in DNL genes may serve as independent prognostic markers for NSCLC patients after surgery.
引用
收藏
页码:7097 / 7103
页数:7
相关论文
共 50 条
  • [1] Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer
    Guo, Xu
    Li, Deyang
    Wu, Yousheng
    Chen, Yibing
    Zhou, Xingchun
    Wang, Xiaoyan
    Huang, Xiaojun
    Li, Xiaofei
    Yang, Hushan
    Xing, Jinliang
    LUNG CANCER, 2015, 87 (02) : 162 - 168
  • [2] Genetic Variants in the Wnt Signaling Pathway Are Not Associated with Survival Outcome of Non-Small Cell Lung Cancer in a Korean Population
    Yoo, Seung Soo
    Hong, Mi Jeong
    Choi, Jin Eun
    Lee, Jang Hyuck
    Baek, Sun Ah
    Lee, Won Kee
    Lee, So Yeon
    Lee, Shin Yup
    Lee, Jaehee
    Cha, Seung Ick
    Kim, Chang Ho
    Cho, Sukki
    Park, Jae Yong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2016, 31 (03) : 463 - +
  • [3] Impact of anesthetic factors on prognosis of patients with non-small cell lung cancer after surgery
    Zhu, Wenzhi
    Li, Shuang
    Ji, Xinqiang
    Tan, Hongyu
    JOURNAL OF THORACIC DISEASE, 2023, 15 (09) : 4869 - 4884
  • [4] Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients
    Dong, Honglin
    Bao, Dengke
    Guo, Xu
    Hu, Jie
    Li, Xiaofei
    Wan, Shaogui
    Xing, Jinliang
    TUMOR BIOLOGY, 2015, 36 (09) : 7151 - 7157
  • [5] Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer
    Huang, Shao-jun
    Wang, Yu-fei
    Jin, Zhi-yong
    Sun, Jia-yang
    Guo, Zhan-lin
    TUMOR BIOLOGY, 2014, 35 (05) : 4023 - 4029
  • [6] Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy
    Suzawa, Ken
    Soh, Junichi
    Takahashi, Yuta
    Sato, Hiroki
    Shien, Kazuhiko
    Yamamoto, Hiromasa
    Kanazawa, Susumu
    Kiura, Katsuyuki
    Miyoshi, Shinichiro
    Toyooka, Shinichi
    SURGERY TODAY, 2019, 49 (07) : 601 - 609
  • [7] Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer
    Li, Liang
    Schaid, Daniel J.
    Fridley, Brooke L.
    Kalari, Krishna R.
    Jenkins, Gregory D.
    Abo, Ryan P.
    Batzler, Anthony
    Moon, Irene
    Pelleymounter, Linda
    Eckloff, Bruce W.
    Wieben, Eric D.
    Sun, Zhifu
    Yang, Ping
    Wang, Liewei
    PHARMACOGENETICS AND GENOMICS, 2012, 22 (02) : 105 - 116
  • [8] Decreased expression of miR-32 is associated with the clinical outcome of non-small cell lung cancer patients
    Sun, Yu
    Cong, Lele
    Zhong, Xiaoming
    Ma, Yushui
    Luo, Ping
    Liu, Miao
    Yang, Huiqiong
    Cong, Xianling
    Fu, Da
    Zhao, Qing
    Liu, Xingdang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (05): : 6021 - 6028
  • [9] Genetic variations in monocarboxylate transporter genes as predictors of clinical outcomes in non-small cell lung cancer
    Guo, Xu
    Chen, Cheng
    Liu, Boya
    Wu, Yousheng
    Chen, Yibing
    Zhou, Xingchun
    Huang, Xiaojun
    Li, Xiaofei
    Yang, Hushan
    Chen, Zhinan
    Xing, Jinliang
    TUMOR BIOLOGY, 2015, 36 (05) : 3931 - 3939
  • [10] A clinical risk model for assessing the survival of patients with stage IA-IIA non-small cell lung cancer after surgery
    Qian, Jia-Yi
    Li, Zhi-Xin
    Wu, Lei-Lei
    Song, Si-Hui
    Li, Chong-Wu
    Lin, Wei-Kang
    Xu, Shu-Quan
    Li, Kun
    Xie, Dong
    JOURNAL OF THORACIC DISEASE, 2022, 14 (11) : 4285 - 4296